On the public citation graph
The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice
0 signed · 140 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.2016.5989openalex-snapshot
Screening for Colorectal Cancer
inferredcites →https://doi.org/10.1001/jama.2018.10897openalex-snapshot
Screening for Cervical Cancer
inferredcites →https://doi.org/10.1016/j.annonc.2020.02.011openalex-snapshot
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
inferredcites →https://doi.org/10.1016/j.canep.2015.10.021openalex-snapshot
European Code against Cancer, 4th Edition: Cancer screening
inferredcites →https://doi.org/10.1016/j.ccell.2021.02.004openalex-snapshot
Multi-cancer early detection: A new paradigm for reducing cancer-specific and all-cause mortality
inferredcites →https://doi.org/10.1016/j.clinimag.2020.05.032openalex-snapshot
Coronavirus disease 2019 (COVID-19) pandemic: Review of guidelines for resuming non-urgent imaging and procedures in radiology during Phase II
inferredcites →https://doi.org/10.1016/j.jtho.2019.08.1092openalex-snapshot
P1.11-19 Trial in Progress: Cancer Screening Study With or Without Low Dose Lung CT to Validate a Multi-Cancer Early Detection Blood Test
inferredcites →https://doi.org/10.1037//0278-6133.21.6.564openalex-snapshot
A brief assessment of concerns associated with genetic testing for cancer: The multidimensional impact of cancer risk assessment (MICRA) questionnaire.
inferredcites →https://doi.org/10.1038/d41573-020-00093-1openalex-snapshot
Impact of COVID-19 on oncology clinical trials
inferredcites →https://doi.org/10.1038/s41586-018-0703-0openalex-snapshot
Sensitive tumour detection and classification using plasma cell-free DNA methylomes
inferredcites →https://doi.org/10.1038/s41586-019-1272-6openalex-snapshot
Genome-wide cell-free DNA fragmentation in patients with cancer
inferredcites →https://doi.org/10.1038/s41698-018-0066-xopenalex-snapshot
Universal cancer screening: revolutionary, rational, and realizable
inferredcites →https://doi.org/10.1038/s43018-020-0043-5openalex-snapshot
Circulating tumor DNA and liquid biopsy in oncology
inferredcites →https://doi.org/10.1056/nejmoa1102873openalex-snapshot
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
inferredcites →https://doi.org/10.1093/annonc/mdz394.074openalex-snapshot
Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA)
inferredcites →https://doi.org/10.1093/ije/dyv175openalex-snapshot
Impact of changing US cigarette smoking patterns on incident cancer: risks of 20 smoking-related cancers among the women and men of the NIH-AARP cohort
inferredcites →https://doi.org/10.1093/jnci/93.14.1054openalex-snapshot
Phases of Biomarker Development for Early Detection of Cancer
inferredcites →https://doi.org/10.1093/jnci/dju289openalex-snapshot
Effects of Screening and Systemic Adjuvant Therapy on ER-Specific US Breast Cancer Mortality
inferredcites →https://doi.org/10.1097/01.ogx.0000549540.69362.81openalex-snapshot
Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement
inferredcites →https://doi.org/10.1126/science.aar3247openalex-snapshot
Detection and localization of surgically resectable cancers with a multi-analyte blood test
inferredcites →https://doi.org/10.1126/science.abb9601openalex-snapshot
Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention
inferredcites →https://doi.org/10.1158/1055-9965.epi-20-1134openalex-snapshot
Modeled Reductions in Late-stage Cancer with a Multi-Cancer Early Detection Test
inferredcites →https://doi.org/10.1177/0272989x18776637openalex-snapshot
Estimation of a Preference-Based Summary Score for the Patient-Reported Outcomes Measurement Information System: The PROMIS ® -Preference (PROPr) Scoring System
inferredcites →https://doi.org/10.1370/afm.942openalex-snapshot
Cumulative Incidence of False-Positive Results in Repeated, Multimodal Cancer Screening
inferredcites →https://doi.org/10.3111/13696998.2013.848208openalex-snapshot
Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population
inferredcites →https://doi.org/10.3322/caac.21557openalex-snapshot
Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening
inferredcites →https://doi.org/10.3748/wjg.v23.i28.5086openalex-snapshot
Colorectal cancer screening: An updated review of the available options
inferredcites →https://doi.org/10.5888/pcd15.170465openalex-snapshot
Patterns and Trends in Cancer Screening in the United States
inferredcites →https://doi.org/10.6004/jadpro.2020.11.2.1openalex-snapshot
The American Cancer Society’s Facts & Figures: 2020 Edition
inferredcites →https://doi.org/10.6004/jnccn.2017.0036openalex-snapshot
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
inferredcites →https://doi.org/10.6004/jnccn.2017.7065openalex-snapshot
Medical Care Costs Associated With Cancer in Integrated Delivery Systems
inferredcites →https://doi.org/10.6004/jnccn.2018.0020openalex-snapshot
Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology
inferredcites →https://doi.org/10.6004/jnccn.2018.0061openalex-snapshot
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
inferredcites →https://doi.org/10.6004/jnccn.2018.0083openalex-snapshot
Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology
inferredcites →https://doi.org/10.7326/m13-2771openalex-snapshot
Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement
inferredcites →https://doi.org/10.7326/m15-2886openalex-snapshot
Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4819273openalex-extracted
Analytical and Clinical Validation of a Circulating Tumor DNA-Based Assay for Multi-Cancer Early Detection
inferred← citeshttps://doi.org/10.1002/cncr.34745openalex-snapshot
The modeling of multicancer early detection (MCED) tests’ residual risk and the challenges of MCED evaluation and implementation
inferred← citeshttps://doi.org/10.1002/cncr.35086openalex-snapshot
Are multicancer early detection screening tests a hoped‐for breakthrough?
inferred← citeshttps://doi.org/10.1002/jgh3.70331openalex-snapshot
Assessment of Circulating Tumor DNA for Early Detection of Hepatocellular Carcinoma in Alpha‐Fetoprotein–Negative Patients With Cirrhotic Nodules
inferred← citeshttps://doi.org/10.1002/uro2.70045openalex-snapshot
Liquid biopsy in genitourinary oncology: Current clinical applications and future prospects across prostate, bladder, and renal cancers
inferred← citeshttps://doi.org/10.1007/978-3-031-32573-1_11openalex-snapshot
Implications of Evolutionary Dynamics for Cancer Treatment and Prevention
inferred← citeshttps://doi.org/10.1007/978-981-19-7630-8_2openalex-snapshot
Breast Cancer Risk Assessment Models and Multi-Cancer Early Detection Tests
inferred← citeshttps://doi.org/10.1007/978-981-95-3682-5_1openalex-snapshot
Liquid Biopsy in Early-Stage Breast Cancer
inferred← citeshttps://doi.org/10.1016/b978-0-12-824010-6.00029-0openalex-snapshot
Liquid biopsy based on circulating tumor DNA for lung cancer: A step toward prevention
inferred← citeshttps://doi.org/10.1016/b978-0-323-95311-5.00008-7openalex-snapshot
Harmonising regulatory requirements for validation of digital health technologies in the United States, EU and United Kingdom
inferred← citeshttps://doi.org/10.1016/b978-0-443-21901-6.00014-8openalex-snapshot
Circulating tumor DNA (ctDNA) as a new and evolving tool in solid organ transplantation
inferred← citeshttps://doi.org/10.1016/j.ajur.2022.11.002openalex-snapshot
Cell-free DNA in the management of prostate cancer: Current status and future prospective
inferred← citeshttps://doi.org/10.1016/j.bbadis.2022.166390openalex-snapshot
Challenges in promoter methylation analysis in the new era of translational oncology: a focus on liquid biopsy
inferred← citeshttps://doi.org/10.1016/j.cmpb.2026.109346openalex-snapshot
Frequency-Domain Dynamic Light Scattering (FEDSA) for in vivo screening of breast tissue abnormalities: A proof-of-concept study
inferred← citeshttps://doi.org/10.1016/j.giec.2023.03.009openalex-snapshot
Blood-Based Biomarkers in the Diagnosis and Risk Stratification of Pancreatic Cysts
inferred← citeshttps://doi.org/10.1016/j.gtc.2025.08.001openalex-snapshot
Biomarkers for Gastric Cancer and Premalignant Gastric Conditions
inferred← citeshttps://doi.org/10.1016/j.hoc.2024.04.004openalex-snapshot
Biomarkers in Cancer Screening
inferred← citeshttps://doi.org/10.1016/j.jlb.2023.100126openalex-snapshot
Harnessing liquid biopsies: Exosomes and ctDNA as minimally invasive biomarkers for precision cancer medicine
inferred← citeshttps://doi.org/10.1016/j.kint.2026.02.039openalex-snapshot
Kidney cancer screening: novel concepts beyond population-level screening
inferred← citeshttps://doi.org/10.1016/j.surge.2023.10.010openalex-snapshot
Risk-stratified screening for the early detection of kidney cancer
inferred← citeshttps://doi.org/10.1016/s0140-6736(23)01700-2openalex-snapshot
Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study
inferred← citeshttps://doi.org/10.1016/s1470-2045(24)00645-4openalex-snapshot
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study
inferred← citeshttps://doi.org/10.1017/s0963180124000744openalex-snapshot
Ethical Considerations and Implications of Multi-Cancer Early Detection Screening: Reliability, Access and Cost to Test and Treat
inferred← citeshttps://doi.org/10.1021/prechem.5c00014openalex-snapshot
Advances in Epigenomic Sequencing and Their Applications in Cancer Diagnostics
inferred← citeshttps://doi.org/10.1038/s41416-021-01498-4openalex-snapshot
Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK
inferred← citeshttps://doi.org/10.1038/s41431-026-02014-zopenalex-snapshot
Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium
inferred← citeshttps://doi.org/10.1038/s41467-024-55428-yopenalex-snapshot
Multimodal cell-free DNA whole-genome TAPS is sensitive and reveals specific cancer signals
inferred← citeshttps://doi.org/10.1038/s41598-025-08986-0openalex-snapshot
Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors
inferred← citeshttps://doi.org/10.1038/s41598-025-19631-1openalex-snapshot
Development of a serum protein biomarker panel for the diagnosis of pancreatic ductal adenocarcinoma using a machine learning approach
inferred← citeshttps://doi.org/10.1038/s41598-026-43178-4openalex-snapshot
Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients
inferred← citeshttps://doi.org/10.1038/s41698-023-00467-9openalex-snapshot
Incidental detection of FGFR3 fusion via liquid biopsy leading to earlier diagnosis of urothelial carcinoma
inferred← citeshttps://doi.org/10.1038/s43856-024-00671-zopenalex-snapshot
Multiomics biomarkers were not superior to clinical variables for pan-cancer screening
inferred← citeshttps://doi.org/10.1055/a-2234-2315openalex-snapshot
Die Rolle der Liquid Biopsy beim primären und metastasierten Mammakarzinom
inferred← citeshttps://doi.org/10.1080/07357907.2023.2173773openalex-snapshot
Clinical validation of a ctDNA-Based Assay for Multi-Cancer Detection: An Interim Report from a Vietnamese Longitudinal Prospective Cohort Study of 2795 Participants
inferred← citeshttps://doi.org/10.1080/10408363.2023.2275150openalex-snapshot
Circulating tumor DNA (ctDNA): can it be used as a pan-cancer early detection test?
inferred← citeshttps://doi.org/10.1080/20565623.2024.2395244openalex-snapshot
A consultation and work-up diagnosis protocol for a multicancer early detection test: a case series study
inferred← citeshttps://doi.org/10.1093/haschl/qxad005openalex-snapshot
Perspectives of private payers on multicancer early-detection tests: informing research, implementation, and policy
inferred← citeshttps://doi.org/10.1093/jamiaopen/ooag093openalex-snapshot
Benchmarking reliability and calibration of LLMs for multi-cancer early detection test communication
inferred← citeshttps://doi.org/10.1093/jnci/djad227openalex-snapshot
Revisiting the standard blueprint for biomarker development to address emerging cancer early detection technologies
inferred← citeshttps://doi.org/10.1093/jnci/djaf218openalex-snapshot
The National Health Service–Galleri multicancer screening trial: explanation and justification of unique and important design issues
inferred← citeshttps://doi.org/10.1093/jncics/pkaf011openalex-snapshot
Tumor localization strategies of multicancer early detection tests: a quantitative assessment
inferred← citeshttps://doi.org/10.1101/2023.09.29.23296336openalex-snapshot
Multimodal cell-free DNA whole-genome analysis combined with TET-Assisted Pyridine Borane Sequencing is sensitive and reveals specific cancer signals
inferred← citeshttps://doi.org/10.1101/2024.03.11.24303683openalex-snapshot
Evaluation of the Multi-Cancer Early Detection (MCED) value of YiDiXie ™ -HS and YiDiXie ™ -SS
inferred← citeshttps://doi.org/10.1101/2025.05.23.25328255openalex-snapshot
AI enabled exome and transcriptome liquid biopsy platform spanning the continuum of care in oncology
inferred← citeshttps://doi.org/10.1109/icssas57918.2023.10331672openalex-snapshot
Comparative Analysis of Machine Learning Models for Early Prediction of Cancer
inferred← citeshttps://doi.org/10.1111/jgh.16182openalex-snapshot
Is this the end of colonoscopy screening for colorectal cancer? An Asia‐Pacific perspective
inferred← citeshttps://doi.org/10.1146/annurev-med-050522-033624openalex-snapshot
Multi-Cancer Early Detection: The New Frontier in Cancer Early Detection
inferred← citeshttps://doi.org/10.1158/1055-9965.epi-23-1470openalex-snapshot
Projecting the Impact of Multi-Cancer Early Detection on Late-Stage Incidence Using Multi-State Disease Modeling
inferred← citeshttps://doi.org/10.1158/1940-6207.capr-22-0469openalex-snapshot
Clonal Evolution in Healthy and Premalignant Tissues: Implications for Early Cancer Interception Strategies
inferred← citeshttps://doi.org/10.1158/1940-6207.capr-24-0468openalex-snapshot
Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution following Multicancer Early Detection Testing in the PATHFINDER Study
inferred← citeshttps://doi.org/10.1172/jci154941openalex-snapshot
Circulating tumor DNA: current challenges for clinical utility
inferred← citeshttps://doi.org/10.1172/jci191942openalex-snapshot
Challenges of early detection of pancreatic cancer
inferred← citeshttps://doi.org/10.1177/18758592241297849openalex-snapshot
Multi-cancer early detection tests: Attributes for clinical implementation
inferred← citeshttps://doi.org/10.1177/21501319251329290openalex-snapshot
Implementation of a Multicancer Detection (MCD) Test in a Tertiary Referral Center in Asymptomatic Patients: An 18-Month Prospective Cohort Study
inferred← citeshttps://doi.org/10.1182/bloodadvances.2024014008openalex-snapshot
Impact of clinical factors on accuracy of ovarian cancer detection via platelet RNA profiling
inferred← citeshttps://doi.org/10.1186/s12916-025-03929-yopenalex-snapshot
Prospective validation study: a non-invasive circulating tumor DNA-based assay for simultaneous early detection of multiple cancers in asymptomatic adults
inferred← citeshttps://doi.org/10.1186/s12917-022-03429-8openalex-snapshot
Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs
inferred← citeshttps://doi.org/10.1186/s12917-026-05950-6openalex-snapshot
A novel, minimally invasive diagnostic test for KIT exon 11 internal tandem duplications in canine cutaneous mast cell tumours II: proof-of-principle applications
inferred← citeshttps://doi.org/10.1186/s13072-025-00595-5openalex-snapshot
Artificial Intelligence in cancer epigenomics: a review on advances in pan-cancer detection and precision medicine
inferred← citeshttps://doi.org/10.1186/s40364-025-00812-zopenalex-snapshot
Development and validation of an integrative 54 biomarker-based risk identification model for multi-cancer in 42,666 individuals: a population-based prospective study to guide advanced screening strategies
inferred← citeshttps://doi.org/10.1186/s43556-025-00361-9openalex-snapshot
Gastrointestinal cancer: molecular pathogenesis and targeted therapy
inferred← citeshttps://doi.org/10.1200/jco.22.00995openalex-snapshot
Regulation of Laboratory-Developed Tests in Preventive Oncology: Emerging Needs and Opportunities
inferred← citeshttps://doi.org/10.1200/op-26-00570openalex-snapshot
Multicancer Detection Tests for Population-Wide Screening of Asymptomatic Individuals: A Systematic Review
inferred← citeshttps://doi.org/10.1200/po.23.00609openalex-snapshot
Optimizing Access to Liquid Biopsy in the Present and Future Cancer Landscape
inferred← citeshttps://doi.org/10.12788/obgm.0266openalex-snapshot
Multi-cancer early detection liquid biopsy testing: A predictive genetic test not quite ready for prime time
inferred← citeshttps://doi.org/10.1371/journal.pone.0266623openalex-snapshot
Clinical validation of a next-generation sequencing-based multi-cancer early detection “liquid biopsy” blood test in over 1,000 dogs using an independent testing set: The CANcer Detection in Dogs (CANDiD) study
inferred← citeshttps://doi.org/10.14218/jerp.2023.00007openalex-snapshot
Multicancer Early Detection Tests for Cancer Diagnosis
inferred← citeshttps://doi.org/10.20892/j.issn.2095-3941.2021.0690openalex-snapshot
Advances in lung cancer screening and early detection
inferred← citeshttps://doi.org/10.21037/tlcr-22-742openalex-snapshot
Current and future applications of liquid biopsy in non-small-cell lung cancer—a narrative review
inferred← citeshttps://doi.org/10.21203/rs.3.rs-5349536/v1openalex-snapshot
Ultra-sensitive, tumor-informed ctDNA profiling in pembrolizumab-treated esophagogastric cancer patients predicts clinical responses
inferred← citeshttps://doi.org/10.21203/rs.3.rs-7395993/v1openalex-snapshot
Detecting hidden threats using longitudinal liquid biopsies
inferred← citeshttps://doi.org/10.3233/tub-230004openalex-snapshot
Screening approaches for lung cancer by blood-based biomarkers: Challenges and opportunities
inferred← citeshttps://doi.org/10.3310/dlmt1294openalex-snapshot
Multi-cancer early detection tests for general population screening: a systematic literature review
inferred← citeshttps://doi.org/10.3322/caac.21765openalex-snapshot
Cancer epigenetics in clinical practice
inferred← citeshttps://doi.org/10.3389/fcell.2021.795735openalex-snapshot
Deconstructing Pancreatic Cancer Using Next Generation-Omic Technologies–From Discovery to Knowledge-Guided Platforms for Better Patient Management
inferred← citeshttps://doi.org/10.3390/biomedicines14010158openalex-snapshot
Liquid Biopsy in Early Screening of Cancers: Emerging Technologies and New Prospects
inferred← citeshttps://doi.org/10.3390/cancers13225615openalex-snapshot
Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer
inferred← citeshttps://doi.org/10.3390/cancers14194818openalex-snapshot
Cell-Free DNA–Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial
inferred← citeshttps://doi.org/10.3390/cancers14205105openalex-snapshot
The Role of ctDNA in Gastric Cancer
inferred← citeshttps://doi.org/10.3390/cancers15102702openalex-snapshot
Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical Applications
inferred← citeshttps://doi.org/10.3390/cancers15102780openalex-snapshot
Biomarker Reproducibility Challenge: A Review of Non-Nucleotide Biomarker Discovery Protocols from Body Fluids in Breast Cancer Diagnosis
inferred← citeshttps://doi.org/10.3390/cancers15194774openalex-snapshot
Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review
inferred← citeshttps://doi.org/10.3390/cancers15225463openalex-snapshot
The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management
inferred← citeshttps://doi.org/10.3390/cancers16061191openalex-snapshot
Cancer Screening: Present Recommendations, the Development of Multi-Cancer Early Development Tests, and the Prospect of Universal Cancer Screening
inferred← citeshttps://doi.org/10.3390/cancers16193335openalex-snapshot
Evolution of Liquid Biopsies for Detecting Pancreatic Cancer
inferred← citeshttps://doi.org/10.3390/cancers17111867openalex-snapshot
Innovative Approaches to Early Detection of Cancer-Transforming Screening for Breast, Lung, and Hard-to-Screen Cancers
inferred← citeshttps://doi.org/10.3390/cells12060935openalex-snapshot
Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests
inferred← citeshttps://doi.org/10.3390/curroncol31010033openalex-snapshot
Plasma Cell-Free Tumor Methylome as a Biomarker in Solid Tumors: Biology and Applications
inferred← citeshttps://doi.org/10.3390/diagnostics12051243openalex-snapshot
The Promise of Multicancer Early Detection. Comment on Pons-Belda et al. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. Diagnostics 2021, 11, 2171
inferred← citeshttps://doi.org/10.3390/ijms24032996openalex-snapshot
DNA Methylation as a Diagnostic, Prognostic, and Predictive Biomarker in Head and Neck Cancer
inferred← citeshttps://doi.org/10.3390/ijms241713219openalex-snapshot
Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
inferred← citeshttps://doi.org/10.3390/jpm13111613openalex-snapshot
Primary Care Patient Interest in Multi-Cancer Early Detection for Cancer Screening
inferred← citeshttps://doi.org/10.3390/jpm16050269openalex-snapshot
Establishment and Performance Evaluation of a Multiplexed TET2–APOBEC-Mediated cfDNA Methylation Detection Workflow Using qPCR and dPCR Readouts
inferred← citeshttps://doi.org/10.3399/bjgp24x739113openalex-snapshot
A multi-cancer early detection (MCED) test: clinical update for GPs
inferred← citeshttps://doi.org/10.3748/wjg.v28.i32.4516openalex-snapshot
Expanding beyond endoscopy: A review of non-invasive modalities in Barrett’s esophagus screening and surveillance
inferred← citeshttps://doi.org/10.3904/kjim.2025.008openalex-snapshot
Updates on lung cancer screening for early detection
inferred← citeshttps://doi.org/10.48083/xbcx3386openalex-snapshot
Kidney Cancer Screening and Epidemiology
inferred← citeshttps://doi.org/10.53730/ijhs.v8ns1.15223openalex-snapshot
Cancer prevention and early detection: Emerging technologies and interventions
inferred← citeshttps://doi.org/10.5694/mja2.52227openalex-snapshot
Screening and prevention of ovarian cancer
inferred← citeshttps://doi.org/10.7143/jhep.50.237openalex-snapshot
Cancer Screening to Date and Future Prospects—Focusing on Scientific Evaluation
inferred← citeshttps://doi.org/10.7326/annals-25-01877openalex-snapshot
Multicancer Detection Tests for Screening
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.